Drug–drug interactions in patients receiving tyrosine kinase inhibitors

Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung Cancer

(2015) Michael P. Chu et al.   Clinical Lung Cancer

FDA-approved small-molecule kinase inhibitors

(2015) Peng Wu et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective

(2014) Roelof W F van Leeuwen et al.   LANCET ONCOLOGY

QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review

(2014) Marzia Locatelli et al.   Targeted Oncology

Preventable and potentially preventable serious adverse reactions induced by oral protein kinase inhibitors through a database of adverse drug reaction reports

(2014) Adeline Egron et al.   Targeted Oncology

Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs

(2013) R W F van Leeuwen et al.   BRITISH JOURNAL OF CANCER

Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)

(2013) Rashmi R. Shah et al.   DRUG SAFETY

Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development

(2013) Gillian S. Smelick et al.   MOLECULAR PHARMACEUTICS

Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?

(2012) N R Budha et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prevalence of the Coprescription of Clinically Important Interacting Drug Combinations Involving Oral Anticancer Agents in Singapore: A Retrospective Database Study

(2012) Yu Ko et al.   CLINICAL THERAPEUTICS

Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature

(2011) R. ter Heine et al.   LUNG CANCER

Clinical pharmacokinetics of tyrosine kinase inhibitors

(2009) Nielka P. van Erp et al.   CANCER TREATMENT REVIEWS

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma

(2009) Fabienne Thomas et al.   EUROPEAN JOURNAL OF CANCER